Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 871 across all filing types
Latest filing 2022-11-02 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于以集中竞价交易方式回购股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from 圣湘生物科技股份有限公司 regarding the progress of a share repurchase program conducted via centralized bidding. It details the board's approval of the share buyback plan, the financial limits, and the status update that no shares have been repurchased as of the specified date. The content focuses on the company's own shares transactions and progress updates on the buyback. There are no financial statements or earnings data, nor is it a report or presentation. This fits the definition of a Transaction in Own Shares (POS) filing, which covers company buyback or sale of its own shares.
2022-11-02 Chinese
圣湘生物科技股份有限公司关于以集中竞价交易方式回购股份的回购报告书
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement from 圣湘生物科技股份有限公司 regarding a share repurchase plan. It includes specifics about the repurchase purpose, amount, price, funding source, board approvals, risk factors, and procedural details. The text repeatedly references the company's plan to buy back shares through centralized bidding, the use of funds, and the impact on shareholding structure. There is no indication that this is a full financial report, earnings release, or management discussion. Instead, it is a comprehensive report on the company's share repurchase activity. According to the filing definitions, this fits best under 'Transaction in Own Shares (POS)', which covers reports of the company buying back or selling its own shares. The document length and detail confirm it is the report itself, not just an announcement of a report publication or a brief notice. Therefore, the correct classification is POS with high confidence.
2022-10-26 Chinese
圣湘生物科技股份有限公司2022年第二次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2022 Second Extraordinary General Meeting of Shareholders" of 圣湘生物科技股份有限公司. It includes detailed meeting instructions, agenda, voting procedures, and a specific proposal regarding the 2022 first three quarters profit distribution plan. The content is focused on the meeting logistics and agenda items for a shareholders meeting, not the actual report or financial statements. The document length is 3637 characters, which is relatively short and consistent with meeting materials rather than a full report. There is no detailed financial statement or comprehensive analysis, but rather meeting notices and proposal for shareholder voting. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual or Extraordinary General Meeting. Therefore, the classification is AGM-R with high confidence.
2022-10-26 Chinese
圣湘生物科技股份有限公司关于回购股份事项前十名股东和前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the shareholding situation of the top ten shareholders and top ten unrestricted shareholders prior to a share repurchase plan approved by the company's board. It references a share repurchase (buyback) scheme and lists detailed shareholding data. The document is relatively short (2128 characters) and focuses on shareholding changes related to a buyback. This fits the category of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares.
2022-10-26 Chinese
圣湘生物科技股份有限公司独立董事关于第二届董事会2022年第三次临时会议相关事宜的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on several board meeting agenda items, including appointment of senior management, accounting estimate changes, share repurchase plan, and cash dividend proposal. It references a specific board meeting date (October 20, 2022) and discusses compliance with laws and regulations. The content is focused on board/management decisions and approvals rather than financial results or report publication. The document length is short (1532 characters), and it is not a report itself but an opinion related to board matters. Therefore, it fits best under Board/Management Information (MANG).
2022-10-20 Chinese
圣湘生物科技股份有限公司关于2022年三季度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the company's profit distribution plan for the third quarter of 2022. It details the dividend payout ratio, the total amount of cash dividends to be distributed, and the approval process including board and supervisory committee meetings. It explicitly states that the plan will be submitted to the shareholders' meeting for approval. The document does not contain full financial statements or comprehensive financial analysis but focuses on dividend distribution details. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and related details to shareholders. The document length is short (1490 characters), and it is not a full financial report or earnings release but a dividend announcement.
2022-10-20 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.